Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 0060 • ACR Convergence 2020
ANCA-associated Vasculitis in Caucasian and Hispanics of the Inland Empire of Southern California
Sandy Lee¹, Patil Injean¹, Paulina Tran², Deepa Panikkath¹ and Christina Downey¹, ¹Loma Linda University Medical Center, Redlands, CA, ²UC Riverside School of Medicine, Riverside, CA
Background/Purpose: ANCA-associated vasculitis (AAV) is often studied in the Caucasian population with few studies looking at the disease in other races. Disease presentation and treatment…
Abstract Number: 1432 • ACR Convergence 2020
Thyroid Disease in Patients with ANCA-Associated Vasculitis
Tanaz Kermani¹, David Cuthbertson², Simon Carette³, Nader Khalidi⁴, Curry L. Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Antoine Sreih¹³, Kenneth Warrington¹² and Peter Merkel¹³, ¹University of California Los Angeles, West Hills, CA, ²University of South Florida, Tampa, ³Division of Rheumatology, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Utah, Salt Lake City, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, ⁸Brigham and Women's, Boston, ⁹University of Pittsburgh, Denver, CO, ¹⁰Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Prior studies have found increased prevalence of thyroid disease in patients with ANCA-associated vasculitis (AAV), especially positive myeloperoxidase (MPO)-ANCA, but a majority of the…
Abstract Number: 0418 • ACR Convergence 2020
Prevalence of Thyroid Disease Among Patients with Vasculitis
Tanaz Kermani¹, David Cuthbertson², Simon Carette³, Nader Khalidi⁴, Curry L. Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Antoine Sreih¹³, Kenneth Warrington¹² and Peter Merkel¹³, ¹David Geffen School of Medicine / University of California, Los Angeles, CA, ²University of South Florida, Tampa, ³Division of Rheumatology, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Utah, Salt Lake City, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, ⁸Brigham and Women's, Boston, ⁹University of Pittsburgh, Denver, CO, ¹⁰Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Previous studies have reported higher risk of thyroid disease in patients with giant cell arteritis (GCA) and ANCA-associated vasculitis (AAV) compared to age- and…
Abstract Number: 1433 • ACR Convergence 2020
Thyroid Disease in ANCA-associated Vasculitis. a Population-based Study
Anna Wilding¹, Rona Smith², David Jayne³, Mårten Segelmark⁴ and Aladdin Mohammad⁵, ¹Lund University, Staffanstorp, Sweden, ²University of Cambridge, Cambridge, United Kingdom, ³Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ⁴Lund University, Lund, ⁵Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden
Background/Purpose: A higher incidence of thyroid disease has been seen in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We aim to assess the incidence…
Abstract Number: 0432 • ACR Convergence 2020
The Effect on Renal Function of the Complement C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
Peter Merkel¹, Pirow Bekker², Huibin Yue², Catherine Kelleher², Thomas Schall² and David Jayne³, ¹University of Pennsylvania, Philadelphia, PA, ²ChemoCentryx, Mountain View, CA, ³Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom
Background/Purpose: Avacopan, a novel, orally-administered selective antagonist of C5aR, was recently evaluated in a pivotal Phase 3 randomized clinical trial where its use in patients…
Abstract Number: 1434 • ACR Convergence 2020
The Role of Sural Nerve Biopsy in the Diagnosis of Systemic Vasculitis – a Retrospective Study from Two Specialized Centres
Karl Gisslander¹, Lars Dahlin², Rona Smith³, David Jayne³ and Aladdin Mohammad⁴, ¹Lund University, Lund, Sweden, Lund, Sweden, ²Department of Translational Medicine – Hand Surgery, Lund University, Malmö, Sweden, Malmö, Sweden, ³Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ⁴Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden
Background/Purpose: Vasculitis of the peripheral nervous system is seen mainly in systemic vasculitis involving small and medium sized vessels and in cases of single-organ vasculitis…
Abstract Number: 0566 • ACR Convergence 2020
Healthcare Utilization and Costs Prior to Diagnosis of ANCA Vasculitis in Medicare Beneficiaries
Shirley Huang¹, Xintong Li², Joehl Nguyen², Jacob Robinson², Susan Hogan³, Vimal Derebail³ and Carolyn Thorpe², ¹University of North Carolina at Chapel Hill, Chapel Hill, ²University of North Carolina Eshelman School of Pharmacy, Chapel Hill, ³University of North Carolina Kidney Center, Chapel Hill
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) vasculitis (AV) is a complex group of autoimmune disorders affecting blood vessels in multiple organ systems. Delays in diagnosis are…
Abstract Number: 1435 • ACR Convergence 2020
Prognostic Factors for Mononeuritis Multiplex Associated with ANCA-associated Vasculitis
Yutaro Hayashi¹, Satoshi Hama², Keisuke Izumi², Mari Ushikubo¹, Misako Konishi³, Yutaka Okano⁴ and Hisaji Ohshima², ¹Tokyo medical center, Tokyo, Japan, ²Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, tokyo, Japan, ³Tokyo medical center, toukyouto Meguroku, Japan, ⁴Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan
Background/Purpose: ANCA-associated vasculitis (AAV) sometimes presents mononeuritis multiplex which worsens the prognosis and activity of daily living in patients. This study aimed to determine theprognostic factorsand…
Abstract Number: 0622 • ACR Convergence 2020
Infection-induced MPO-ANCA Associated Vasculitis: A Systematic Review of Published Case Reports
Konstantinos Parperis¹, Loukas Kakoullis², Eleni Papachristodoulou³ and George Panos³, ¹University of Arizona College of Medicine Phoenix and University of Cyprus Medical School, Phoenix, ²University of Patras School of Health Sciences, Patras, Akhaia, Greece, ³University of Cyprus Medical School, Nicosia, Nicosia, Cyprus
Background/Purpose: Anti-myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA) has been implicated in the pathogenesis of microscopic polyangiitis (MPA) and an MPO-ANCA associated glomerulonephritis; both conditions are…
Abstract Number: 1437 • ACR Convergence 2020
Measuring Disease Activity and Functional Status in Patients with Granulomatosis with Polyangiitis (Wegener’s) (GPA)
Kinanah Yaseen¹, Isaac Briskin¹ and Rula Hajj-ali², ¹Cleveland Clinic Foundation, Cleveland, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Variable association between vasculitis activity and patient reported outcomes was reported in small groups of Granulomatosis with polyangiitis (GPA) patients in the literature so…
Abstract Number: 1032 • ACR Convergence 2020
Epidemiology and Geographic Evaluation of ANCA-associated Vasculitis (AAV) at a Rural Academic Health Center Utilizing an Electronic Health Record (EHR)
Eva Rottmann¹, Jason Bankert², Andrea Berger², Lester Kirchner², Joseph Dewalle², Marissa Meissner³, Jason George², Ion Dan Bucaloiu², Jaya Prakash Sugunaraj², Sudheer Penupolu² and David Bulbin¹, ¹Geisinger Health System, Danville, PA, ²Geisinger Medical Center, Danville, PA, ³Geisinger Medical Center, Danville
Background/Purpose: ANCA-associated vasculitis has a reported prevalence ranging from 3.2 to 9.1 cases per 100,000 individuals, but little is known of geographic variations. The aim of…
Abstract Number: 1438 • ACR Convergence 2020
Rituximab Immunogenicity in ANCA-associated Vasculitis (RITUXIMAV)
Jason Springer¹ and Ryan Funk², ¹University of Kansas Medical Center, Overland Park, KS, ²UNIVERSITY OF KANSAS, Kansas City, KS
Background/Purpose: Rituximab (RTX), an anti-CD20 chimeric monoclonal antibody, has been shown to be an effective maintenance therapy for granulomatosis with polyangitiis (GPA) and microscopic polyangiitis…
Abstract Number: 1417 • ACR Convergence 2020
Risk of Relapse of ANCA-associated Vasculitis in Patients of 75 Years and Older: A Retrospective Study
Sara Thietart¹, Guillaume Beinse², Perrine Smets³, Alexandre Karras⁴, Carole Philipponnet⁵, Jean-François Augusto⁶, Khalil El Karoui⁷, Rafik Mesbah⁸, Dimitri Titeca Beauport⁹, Mohamed Hamidou¹⁰, Pierre-Louis Carron¹¹, Julien Campagne¹², Karim Sacre¹³, Pascal Cohen¹, Eric Liozon¹⁴, Claire Blanchard-Delaunay¹⁵, Alex Kostianovsky¹⁶, Christian Pagnoux¹⁷, Luc Mouthon¹, Loïc Guillevin¹⁸, Benjamin Terrier¹ and Xavier Puéchal for the French Vasculitis Study Group¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, ²Inserm UMR 1138, Centre de Recherche des Cordeliers, Paris, France, ³Department of Internal Medicine, Centre Hospitalier Universitaire Clermont-Ferrand Hôpital Gabriel-Montpied, Clermont Ferrand, France, ⁴Department of Nephrology, Hôpital Européen Georges Pompidou, Paris, France, ⁵Department of Nephrology, CHU Clermont-Ferrand, Clermont-Ferrand, Clermont Ferrand, France, ⁶Department of Nephrology-Dialysis-Transplantation, CHU Angers, Angers, France, ⁷Department of Nephrology and Transplantation, Hôpital Universitaire Henri-Mondor, Creteil, France, ⁸Department of Nephrology, CH Boulogne-sur-Mer, Boulogne-Sur-Mer, France, ⁹Department of Nephrology, Amiens University Medical Center, Amiens, France, ¹⁰Department of Internal Medicine, Hôtel-Dieu, CHU Nantes, Nantes, France, ¹¹Department of Nephrology-Dialysis-Transplantation, CHU Grenoble-Alpes, Grenobles, France, ¹²Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France, ¹³Département de Médecine Interne, Hôpital Bichat, APHP, Paris, France, ¹⁴Department of Internal Medicine and Clinical Immunology, Limoges University Hospital, Limoges, France, ¹⁵Department of Internal Medicine, CH, Niort, France, ¹⁶Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno", Buenos Aeres, Argentina, ¹⁷Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁸Department of Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France
Background/Purpose: ANCA-associated vasculitis (AAV) frequently occurs among older patients, with different clinical presentations than the younger. Little is known on the outcome of older patients…
Abstract Number: 1439 • ACR Convergence 2020
Proteinase 3-Reactive B Cell Pool Restructuring After Rituximab and Risk of Relapse in Severe PR3-ANCA-Associated Vasculitis
Alvise Berti¹, Sophie Hillion², Marta Casal Moura¹, Amber Hummel¹, Eva Carmona¹, Tobias Peikert¹, Carol Langford³, Peter A. Merkel⁴, Paul Monach⁵, Philip Seo⁶, Robert Spiera⁷, Eugene St Clair⁸, Fernando C. Fervenza¹, Kristina Harris⁹, John H. Stone¹⁰, Jacques-Olivier Pers¹¹, Ulrich Specks¹ and Divi Cornec¹², ¹Mayo Clinic, Rochester, MN, ²Brest University, Brest, Bretagne, France, ³Cleveland Clinic, Moreland Hills, OH, ⁴Division of Rheumatology University of Pennsylvania, Philadelphia, PA, ⁵Brigham and Women's, Boston, ⁶Johns Hopkins University, Baltimore, MD, ⁷Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, ⁸Duke University, Durham, NC, ⁹Immune Tolerance Network, Bethesda, MD, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹¹University of Brest, Brest, France, ¹²Rheumatology Department, Brest University Hospital, Brest, France
Background/Purpose: In ANCA-associated vasculitis (AAV) B cells play a central pathogenic role and are instrumental for the production of ANCA, which are thought to mediate…
Abstract Number: 1418 • ACR Convergence 2020
Clinical Presentations and Follow-up Results of Granulomatosis with Polyangiitis: An Analysis of 8 Years Clinical Experience with 220 Patients from a National Referral Center
Seyed Behnam Jazayeri¹, Farzaneh Kianifar², Samira Alesaeidi², Soheil Tavakolpour³, Amir Teimourpour⁴ and Sasan Dabiri², ¹Tehran university of medical scienses, Tehran, Iran, ²Tehran university of medical sciences, Tehran, Iran, ³Dana-faber cancer institute, Harvard Medical School, Boston, MA, ⁴Department of epidemiology and bio-statistics, Tehran university of medical sciences, Tehran, Iran
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a rare and life-threatening autoimmune disease. Due to the extremely low prevalence of GPA, monitoring of clinical characteristics and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].